Table 7.
Differences in baseline characteristics in subjects with improved HRQL 1-year after lung transplantation compared to those who did not improve
| SF12-PCS | SF12-MCS | AQ20-R | EQ5D | EQVAS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Not improved |
Improved | Not Improved |
Improved | Not Improved |
Improved | Not Improved |
Improved | Not improved |
Improved | ||
| N (%) | 30 (21%) | 110 (79%) | 93 (66%) | 47 (34%) | 16 (11%) | 125 (89%) | 60 (43%) | 81 (57%) | 27 (25%) | 82 (75%) | |
| Diagnosis | * | * | |||||||||
| Group A (COPD) | 7 (23%) | 16 (15%) | 21 (23%) | 2 (4%) | 1 (6%) | 22 (18%) | 14 (23%) | 9 (11%) | 6 (22%) | 11 (13%) | |
| Group B (PAH) | 2 (7%) | 3 (3%) | 4 (4%) | 1 (2%) | 3 (19%) | 2 (2%) | 5 (8%) | 0 (0%) | 2 (7%) | 2 (2%) | |
| Group C (CF) | 3 (10%) | 11 (10%) | 8 (9%) | 6 (13%) | 0 (0%) | 14 (11%) | 3 (5%) | 11 (14%) | 0 (0%) | 11 (13%) | |
| Group D (PF) | 18 (60%) | 80 (73%) | 60 (65%) | 38 (81%) | 12 (75%) | 87 (70%) | 38 (63%) | 61 (75%) | 19 (70%) | 58 (71%) | |
| BMI | 25.4 (23.9, 29.5) |
25.7 (21.4, 28.3) |
26.2 (22.8, 28.7) |
24.4 (22.1, 27.5) |
28.0 (23.3, 29.8) |
25.5 (22.2, 28.2) |
26.7 (23.1, 30.3)* |
24.4 (21.1, 27.5)* |
26.2 (24.2, 30.4) |
25.1 (21.4, 28.1) |
|
| LAS | 40.5 (35.4, 62.4) |
46.3 (39.4, 63.6) |
44.1 (36.4, 55.8)* |
56.9 (42.8, 79.0)* |
39.0 (35.0, 55.9) |
46.5 (39.6, 65.4) |
40.5 (35.4, 52.7)* |
52.4 (40.4, 73.7)* |
42.9 (37.3, 56.1) |
48.4 (40.0, 67.0) |
|
| FEV1 | 1.33 (0.91, 2.30) |
1.30 (0.89, 1.73) |
1.22 (0.89, 1.73) |
1.46 (0.93, 1.80) |
2.17 (1.15, 2.48)* |
1.29 (0.85, 1.72)* |
1.33 (0.95, 2.13) |
1.30 (0.87, 1.69) |
1.47 (0.91, 2.00) |
1.31 (0.85, 1.74) |
|
| 6MWD | 261 (149, 363) |
281 (150, 377) |
305 (191, 375)* |
215 (95, 366)* |
325 (223, 365) |
278 (146, 376) |
320 (247, 376)* |
219 (112, 370)* |
280 (222, 366) |
289 (155, 379) |
|
| Hospitalized at transplant** |
8 (27%) | 33 (30%) | 20 (21%)* | 21 (45%)* | 2 (13%) | 39 (31%) | 7 (12%)* | 34 (42%)* | 6 (22%) | 28 (34%) | |
|
Intubated at transplant |
2 (7%) | 12 (11%) | 7 (8%) | 7 (15%) | 0 (0%) | 14 (11%) | 2 (3%)* | 12 (15%)* | 2 (3%) | 12 (15%) | |
Data presented as median (IQR)
Improvement defined as increase by twice the minimally clinically important difference for each HRQL instrument
Differences that were statistically significant noted by bold and asterisk.
Subject was already hospitalized at the time of transplant (e.g., not called in from home for transplant surgery)
COPD = Chronic Obstructive Pulmonary Disease; PAH = Pulmonary Arterial Hypertension; CF = Cystic Fibrosis; PF = Pulmonary Fibrosis; BMI = Body Mass Index; 6MWD = six-minute walk distance; FEV1 = forced expiratory capacity in 1 second; LAS = Lung Allocation Score; SF12-PCS = Medical Outcomes Study Short Form 12 Physical Component Summary scale (MCID = 5) ; SF12-MCS = Medical Outcomes Study Short Form 12 Mental Component Summary scale (MCID = 5) ; AQ20-R = Airway Questionnaire 20 - revised (MCID = 1.75); EQ5D = Euroqol 5D (MCID = 0.06) ; EQVAS = Euroqol Visual Analog Scale (MCID =0.06); deaths were assigned a score of 0.